The IN VIVO Blog
In VIVO Blog Spot. ...
Read Invivoblog.blogspot.com news digest here: view the latest In VIVO Blog Spot articles and content updates right away or get to their most visited pages. Invivoblog.blogspot.com is not yet rated by Alexa and its traffic estimate is unavailable. It seems that In VIVO Blog Spot content is notably popular in USA. We haven’t detected security issues or inappropriate content on Invivoblog.blogspot.com and thus you can safely use it. Invivoblog.blogspot.com is hosted with Google LLC (United States) and its basic language is English.
Content verdict: Safe
Website availability: Live
Language: English
Last check:
-
N/A
Visitors daily -
N/A
Pageviews daily -
5
Google PR -
N/A
Alexa rank
Best pages on Invivoblog.blogspot.com
-
Here at Deals of the Week, we don’t often take note explicitly of buyouts outside the biopharma sphere. But one well-publicized tech deal last month piqued our interest – and it parallels another rece...
-
The IN VIVO Blog: Merck Says Goodbye to Independent Biosimilars Unit
Merck BioVentures, the biosimilars endeavor set up by Merck & Co. in late 2008, is being subsumed into the biologics and vaccines division of Merck Research Laboratories. Mike Kamarck, who has led Bio...
-
The IN VIVO Blog: New Drug Approvals at the Half: 2008 Looks A Lot Like 2007, And That Isn’t Good
Wednesday, July 30, 2008 So do you want the good news or the bad news? Let's start with the bad. So far, the number of new molecular entities and novel biologics approved by the Food & Drug Administra...
Invivoblog.blogspot.com news digest
-
9 years
The IN-VIVO Blog will no longer be publishing content. For the latest health-care industry news, analysis and much more, be sure to visit www.pharmamedtechbi.com!
Copyright © 2014 Informa Business Information, Inc., an Informa Company. All rights reserved. www.pharmamedtechbi.com... -
10 years
Deals of the Week Takes Stock in M&A
Here at Deals of the Week, we don’t often take note explicitly of buyouts outside the biopharma sphere. But one well-publicized tech deal last month piqued our interest – and it parallels another recent pharma deal in a way we found curious...
-
10 years
What Is the Buoyant Biotech IPO Scene Doing to Private Biotech M&A Trends? FOTF ...
Despite a slight slowdown, there's considerable cash already sloshing around the biotech IPO space. There's (still!) plenty more stacked up in investor suitcases from California to the New York Island just waiting to back anything with a pulse. The momentum...
-
10 years
Stakeholders in Consumer Genomics, Read This
Noting a flurry of recent commentaries in peer-review journals, our February Science Matters column in START-UP (link here, free access) discussed how the personal genomics company 23andMe has accelerated the consumer genomics debate through its dust...
Domain history
| Web host: | Google LLC |
| Registrar: | MarkMonitor Inc. |
| Registrant: | Google LLC |
| Updated: | June 29, 2023 |
| Expires: | July 31, 2024 |
| Created: | July 31, 2000 |
Whois record
Safety scores
Trustworthiness
GoodChild safety
N/A
